Skip to main content
Caplight Logo









iECURE

iECURE

Private
Blue Bell, PennsylvaniaHealthcare & Life Scienceshttps://iecure.com/

Last Round

Series A

Extension

Nov 30, 2022

Total Funding Raised

$115M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

iECURE is a biotechnology company developing genome editing therapies for rare, life-threatening genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene editingin vivo gene therapyrare diseasebiotech startupornithine transcarbamylase deficiencyOTC deficiencyclinical trialsgenetic medicinepediatric liver diseasegenomic medicinebiopharmametabolic diseasegene therapy pipelineclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iECURE Comparables

Compare iECURE with similar companies based on industry and business-model similarity.

iECURE comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Genespire
79%
Precision BioSciences
74%
Vivet Therapeutics
74%

iECURE Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionNov 30, 2022
Series ASep 9, 2021

Key People

Founding team and executive leadership

Joseph Truitt

Chief Executive Officer

Executive Team

Paul Firuta

Chief Operating Officer

Executive Team

iECURE Investors

Notable investors and investment history

iECURE investors
InvestorRounds
LYFE CapitalSeries A Extension
OrbiMedSeries A Extension, Series A
Versant VenturesSeries A Extension, Series A
Novo HoldingsSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 53% MoM, reaching 2.8K.

  • Oct 2, 2025

    Presenting ECUR-506 data at the American Society of Human Genetics Annual Meeting.

iECURE Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

iECURE Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about iECURE's valuation, stock price, and market status.

Firmographic Details

HeadquartersBlue Bell, Pennsylvania
Employee Range38
Year Founded2020
Last FundingNov 30, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?